GZD824 Dimesylate is a potent inhibitor of BCR-ABL tyrosine kinase, including the T315I mutant form, which is commonly associated with resistance to other kinase inhibitors in chronic myeloid leukemia (CML). It is primarily used in research settings for the development of targeted therapies against CML and other hematological malignancies driven by ABL kinase activity. Due to its high selectivity and efficacy in overcoming drug resistance, GZD824 Dimesylate serves as a valuable tool compound in preclinical studies evaluating signaling pathways and resistance mechanisms in leukemia cells. It has shown strong antiproliferative effects in cell-based assays and has demonstrated tumor growth inhibition in animal models of CML, supporting its potential as a therapeutic candidate in oncology drug development.